Training in the use of a heat-stable uterotonic

Training and IEC resources to support the safe and effective use of an innovative uterotonic in Africa

Although there has been a substantial reduction of maternal mortality since 2000, over 800 women are dying each day from complications in pregnancy and childbirth. Sub-Saharan Africa and South Asia, account for 86% of maternal deaths worldwide. Postpartum haemorrhage (PPH) is the major source of maternal mortality and morbidity.

Carbetocin FerringTM (heat-stable carbetocin) is a uterotonic that has been recommended by the WHO for the prevention of PPH in settings where oxytocin, the current standard of care, is not available or of insufficient quality. The product is particularly suited to environments with high temperatures and suboptimal cold chain, as it is the only injectable uterotonic that can remain stable in humid and hot climates. Its use should be closely monitored, as it is a potent uterotonic causing strong and long-lasting uterine contractions which may be harmful to the unborn child if administered prior to childbirth.

In targeted low-and middle-income countries, there is a strong need for information and training of end-users, i.e., medical staff (midwives, obstetricians, nurses) and policy makers, to ensure safe and efficient use of the drug.

EpiLinks has developed a training package and information, communication education (IEC) resources for Carbetocin FerringTM, to be made available to ministries of health and professional organisations in African implementing countries. Clear, accurate, adapted and visually compelling resources were developed through an interactive and iterative process, including training needs assessment, development of an ad hoc training strategy and review by relevant field assessors.


Date: 2020-2021

Ferring Pharmaceuticals


 Isabelle Delrieu

Location: Africa